Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought ...Middle East

News channel - News
Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought
By MICHELLE CHAPMAN AP Business Writer Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products. Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion. Its prior forecast was for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for Covid-19-related products and inventory write-offs. The company previously expected $3.25 to $3.45 per share. The post Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought appeared first on News Channel 3-

Hence then, the article about pfizer trims expectations for 2023 with sales of covid 19 vaccine treatment weaker than thought was published today ( ) and is available on News channel ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News